Market: According to Grand View Research, the global obesity therapeutics market is valued at 15.9 billion US dollars in 2024 and is projected to grow to 60.5 billion US dollars by 2030. Currently, therapeutic and safety advantages in the GLP-1...
The Company is developing orticumab for secondary prevention of cardiac events after acute coronary syndrome (ACS). In 2024, Abcentra published promising clinical data from a phase 2a pilot study, which established clinical proof-of activity of...
ophthalmic solution was approved as dry eye drug therapy in the United States and in Canada in May 2023 and September 2024, respectively. About Hengrui Pharma: Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global...
the development of optimized outpatient care models. Additionally, "Guidelines for the Diagnosis and Treatment of Obesity (2024 Edition)" recommended pharmacotherapy when lifestyle interventions fail to meet weight loss goals. The "Guidelines for...
Bioscience and a meaningful recognition of the outstanding work delivered by our global operations team. Alongside our 2024 Excellence in Client Services and Partnership Award, these accolades highlight our unwavering commitment to serving clients...
2025 would like to welcome all the pharmaceutical professionals and companies to speak at our prestigious Pharma Summit 2024 slated on June 23 - 24, 2025. The Global Pharma Tech Summit 2025 would like to welcome all the pharmaceutical professionals...
were eligible for R-ICE and ASCT, and had received ≥1 prior line of treatment. At the time of data cutoff (December 18, 2024), median follow-up was 11 months (range, 6−15). Among the 31 patients treated with epcoritamab 48 mg + R-ICE, 61 percent...
with a median follow-up for responses of 19 months, the longest DOR was observed at 30.4 months and ongoing as of October 2024. Given the single-arm nature of the TRUST clinical studies, median progression-free survival (PFS) is not provided in the...
designation received for the HADLIMA low-concentration (40 mg/0.8 mL) prefilled syringe and single-dose vial in June 2024.1 With today’s additional interchangeability designations, HADLIMA is now interchangeable with all presentations of the...
associated with septic shock. The product launch adds to the company’s offerings of Epinephrine Injection. In December 2024, Fresenius Kabi introduced the first generic version of Epinephrine, USP, in a 1 mg per mL vial for U.S. customers. “We are...
partnership for the ustekinumab biosimilar covering key global markets. The drug received FDA approval in September 2024 and has been available in the U.S. since March 2025. Otulfi (ustekinumab-aauz) is a human monoclonal antibody that targets the...
platform has shaped the development of immunoregulatory therapeutics like omilancor, NX-13 (acquired by Abbvie in March 2024) and NIM-1324. About NIMML: The NIMML Institute is a 501 (c) (3) non-profit foundation dedicated to combining advanced...
received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking in January 2024. Dr. Uday N. Kumar, Founder, President, and CEO of Element Science, reflected on the achievement, "The Jewel Patch-WCD is...
technology platforms. Mr. Messerlian joined Creyon's Board of Directors as Executive Chairman and Acting CEO in early fall 2024. He brings extensive experience in company building and board leadership, having served in senior roles across multiple...
coming weeks. The CE Mark follows the recent approval of Optune Lua by the U.S. Food and Drug Administration in October 2024. Data Supporting the CE Mark of Optune Lua: The CE Mark approval was supported by data from the Phase 3 LUNAR trial that...
tumor-informed MRD solution for clinical use to support recurrence risk stratification. Labcorp Plasma Detect launched in 2024 for biopharma use to support exploratory and investigational studies. The test combines a WGS approach, without the need...
mobile-friendly, data-driven dashboard. The innovative system was first used shortly after achieving FDA clearance in late 2024 and has been rapidly adopted by likeminded organizations across the nation ever since. Now, over 12 OPOs stock the...
Director Dr. Gernot Wolfram. With more than 40 years of experience, RECIPE is a highly respected, profitable company with 2024 revenues of more than fifteen million dollars. The majority investment and strategic collaboration immediately enhances...
that dual inhibition of CXCR4 with GPC-100 and beta-2 adrenergic receptor blockade led to improved chemotherapy response (2024 American Society of Hematology Annual meeting : Poster #2758). This therapeutic approach is protected by an expanded...
nationally ranked No. 1 in orthopedics (for the 15th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2024-2025), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report “Best Children’s...
